ASX-Dividend-Report-Banner

Lunit Joins as an Associate Partner with the World Economic Forum

November 01, 2023 12:00 AM AEDT | By Cision
 Lunit Joins as an Associate Partner with the World Economic Forum
Image source: Kalkine Media

- Lunit joins as an Associate Partner of the World Economic Forum, propelling global expansion and collaboration in the realm of AI-driven cancer care

SEOUL, South Korea, Oct. 31, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, has expanded its collaboration with the World Economic Forum by joining as an Associate Partner of the forum.

This achievement marks one of the first instances in Asia and among medical AI companies worldwide, where a company has progressively elevated its collaboration with the forum from its initial status as a Technology Pioneer to an Associate Partner. 

Lunit's journey with the forum began in 2020 when it joined as a member of the Technology Pioneer community, earning recognition as one of the 100 leading global tech companies—the sole Korean company on the prestigious list of the year.

Building upon this foundation, in 2022, Lunit solidified its position as a key player in the global AI-driven healthcare landscape by becoming a member of the forum's Unicorn community. In this capacity, Lunit shared insights into the future of AI-driven global healthcare during the forum's events, including annual meetings in Davos, Switzerland and in Tianjin, China.

"As a global platform, the Forum is thrilled to welcome companies like Lunit in their mission to combat cancer through AI and promote the best possible healthcare, contributing to the well-being of individuals in societies and nations," said Dr. Shyam Bishen, Head of the Centre for Health & Healthcare at the World Economic Forum.

"The partnership extension, especially the unique access to a global platform at the highest level at forum meetings, strongly supports our commitment to advancing the landscape of the entire cycle of cancer care through AI-driven solutions," said Brandon Suh, CEO of Lunit. "We are excited to harness the network to accelerate our expansion, make significant strides in combating one of the most formidable global health challenges - cancer -, and addressing inequities in healthcare access."

Lunit's dedication to forming global alliances aligns with its mission to combat cancer through AI solutions for precision diagnostics and treatment support. The flagship Lunit INSIGHT suite for early detection of chest and breast cancer is now operational in approximately 2,500+ hospitals and medical institutions across 40+ countries, marking significant progress in advancing the field of medical AI.

About Lunit

Lunit is a deep learning-based medical AI company on a mission to conquer cancer. Our focus is on developing AI solutions for precision diagnostics and therapeutics, ensuring the right diagnosis, and treatment, at the right cost for each patient. Lunit is devoted to developing advanced medical image analytics and AI-based biomarkers via cutting-edge technology.

Founded in 2013, Lunit has been acknowledged around the world for its advanced, state-of-the-art technology and its application in medical images. As a medical AI company grounded on clinical evidence, the company's findings are presented in major peer-reviewed journals, such as the Journal of Clinical Oncology and JAMA Network Open, and global conferences, including ASCO and AACR.

After receiving FDA clearance and the CE Mark, our flagship Lunit INSIGHT suite is clinically used in approximately 2,500+ hospitals and medical institutions across 40+ countries. Lunit is headquartered in Seoul, South Korea, with offices and representatives worldwide. For more information, please visit lunit.io

About World Economic Forum

The World Economic Forum is the International Organization for Public-Private Cooperation. The Forum engages the foremost political, business, cultural, and other leaders of society to shape global, regional, and industry agendas. It was established in 1971 as a not-for-profit foundation and is headquartered in Geneva, Switzerland. It is independent, impartial, and not tied to any special interests.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.